Eagle Genomics secures £17.4m Series B funding led by abrdn to advance its TechBio platform
The funding round was led by abrdn and will support platform development and international expansion.
Share allotment filed at Companies House
Eagle Genomics is a bioinformatics company based in Cambridge that provides software solutions to accelerate research and development in the life sciences sector.
Eagle Genomics has secured £17.4m in the first close of its Series B funding round, led by abrdn with continued participation from Environmental Technologies Fund and a consortium headed by Granpool Innovative Investments. The funds will be deployed to support platform development, drive international expansion, and deepen client impact.
The Cambridge-based business applies network science and next-generation graph technology to biological discovery, addressing sustainability and innovation challenges across industries such as food and nutrition, agbio, beauty, and biopharma. The current funding round remains open to accommodate additional participation up to a further USD 10m.
From the founder
"We are the pre-eminent platform business using next-generation graph technology and network science to drive the Bioeconomy. We are seeking to support our enterprise customers as they strive to achieve more sustainable and impact-orientated innovation outcomes. The current scale-up funding will enable us to accelerate the Bioeconomy through the digital reinvention of science."
Anthony Finbow
CEO at Eagle Genomics
Use of funds
- 01Continue product development
- 02Expand into international markets
Investors
Categories
About the company
Eagle Genomics
Eagle Genomics develops bioinformatics software for pharmaceutical and life science research.